MedTrace Logo

KPs Supplement for Inflammation, Oxidative Stress and Lipid Abnormalities in CKD Patients.

NCT07260292 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 165

Last updated 2025-12-17

No results posted yet for this study

Summary

This clinical investigation is designed to evaluate the potential therapeutic effects of kefir peptides as an adjunct intervention for chronic kidney disease (CKD) and clinical proteinuria. Patients diagnosed with stage 3 or 4 CKD will receive a three-month course of kefir peptide supplementation. Throughout the intervention period, the investigator will monitor renal function markers (blood urea nitrogen, serum creatinine), proteinuria (urine protein-to-creatinine ratio), inflammatory indicators (high-sensitivity C-reactive protein), and additional biochemical parameters relevant to CKD progression.

Conditions

  • Chronic Kidney Disease Stage 3
  • Chronic Kidney Disease Stage 4
  • Proteinuria

Interventions

DIETARY_SUPPLEMENT

KEFPEP®

oral administration at a daily dosage of 2.4 grams for 12 weeks

DIETARY_SUPPLEMENT

Placebo

using regular yogurt powder as a substitute for KPs

Sponsors & Collaborators

  • Jen Ai Hospital

    collaborator UNKNOWN

  • National Chung Hsing University

    lead OTHER

Principal Investigators

  • YU-HSIEN LIU, Master · Jen Ai Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
30 Years
Max Age
82 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-08-01
Primary Completion
2023-12-30
Completion
2024-08-01

Countries

  • Taiwan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07260292 on ClinicalTrials.gov